Literature DB >> 29262340

RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.

Nicole Glodde1, Michael Hölzel2.   

Abstract

Mutant RAS is a major oncoprotein in human cancer and PD-L1 is a key driver of cancer immune evasion. In this issue of Immunity, Coelho et al. (2017) demonstrate that oncogenic RAS signaling promotes tumor immune escape by stabilizing PD-L1 mRNA.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29262340     DOI： 10.1016/j.immuni.2017.12.001

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  4 in total

Review 1.  Uncovering the Role of RNA-Binding Proteins in Gene Expression in the Immune System.

Authors:  Manuel D Díaz-Muñoz; Martin Turner
Journal:  Front Immunol       Date:  2018-05-23       Impact factor: 7.561

2.  Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.

Authors:  Jörg Hänze; Moritz Wegner; Elfriede Noessner; Rainer Hofmann; Axel Hegele
Journal:  Target Oncol       Date:  2020-06       Impact factor: 4.493

3.  Correlation of PIK3CA mutation with programmed death ligand-1 (PD-L1) expression and their clinicopathological significance in colorectal cancer.

Authors:  Ae Ri Ahn; Kyoung Min Kim; Kyu Yun Jang; Woo Sung Moon; Gi Won Ha; Min Ro Lee; Myoung Ja Chung
Journal:  Ann Transl Med       Date:  2021-09

4.  Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood.

Authors:  Corinna U Keber; Marcus Derigs; Carolin Schultz; Moritz Wegner; Susanne Lingelbach; Viktoria Wischmann; Rainer Hofmann; Carsten Denkert; Axel Hegele; Jörg Hänze
Journal:  Cancer Immunol Immunother       Date:  2022-02-20       Impact factor: 6.630
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.